Prospective Clinical Evaluation of Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

Summary

The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).

Description

Eligibility

Age range

Not specified

Sex

All

Healthy volunteers

No

Interventions

• Other
  Non-Metastatic and Resectable

  Blood Draw Timepoints: * Before any treatment begins * After Neo-adjuvant therapy (only if you receive this type of therapy) * After local surgery * After Adjuvant therapy (only if you receive this type of therapy) * Follow up after adjuvant therapy: at Months 3, 6, 9, 12, 15, 18, and 24 * After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis

• Other
  Metastatic and Un-resectable

  Blood Draw Timepoints: * Before any treatment begins * During standard of care disease evaluation visits for up to 24 months

• Other
  No evidence of disease, under surveillance

  Blood Draw Timepoints: * From completion of treatment- at Months 3, 6, 9, 12, 15, 18, and 24; depending on when you enroll into the study you will start at the next timepoint in this schedule * After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis

• Other
  ALT or WDLS

  Blood Draw Timepoints: • Collect once after surgery (up to six weeks after surgery)

Locations (2)